(0.33%) 5 116.69 points
(0.33%) 38 365 points
(0.36%) 15 986 points
(-0.93%) $83.07
(5.56%) $2.03
(0.35%) $2 355.30
(0.46%) $27.66
(4.04%) $959.35
(-0.26%) $0.932
(-0.42%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.01%
@ $73.34
発行日: 15 2月 2024 @ 00:26
リターン: -4.53%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: -1.89 %
Live Chart Being Loaded With Signals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...
Stats | |
---|---|
本日の出来高 | 81 047.00 |
平均出来高 | 174 795 |
時価総額 | 1.26B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $1.130 ) 2024-05-02 |
Last Dividend | $0.456 ( 2010-07-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | 23.11 |
ATR14 | $0.0770 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-24 | Kozarich John W | Buy | 2 893 | Common Stock |
2024-04-24 | Kozarich John W | Sell | 2 893 | Non-Qualified Stock Option (right to buy) |
2024-03-25 | Davis Todd C | Buy | 3 556 | Common Stock |
2024-03-25 | Davis Todd C | Buy | 2 156 | Common Stock |
2024-03-25 | Davis Todd C | Buy | 2 855 | Common Stock |
INSIDER POWER |
---|
76.79 |
Last 99 transactions |
Buy: 847 979 | Sell: 102 779 |
ボリューム 相関
Ligand Pharmaceuticals 相関 - 通貨/商品
Ligand Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $131.31M |
総利益: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2023 |
収益: | $131.31M |
総利益: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2022 |
収益: | $196.25M |
総利益: | $143.42M (73.08 %) |
EPS: | $-0.310 |
FY | 2021 |
収益: | $277.13M |
総利益: | $214.96M (77.56 %) |
EPS: | $2.22 |
Financial Reports:
No articles found.
Ligand Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $9.36 | 2007-04-03 |
Last Dividend | $0.456 | 2010-07-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $9.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.65 | -- |
Div. Sustainability Score | 8.02 | |
Div.Growth Potential Score | 1.515 | |
Div. Directional Score | 4.77 | -- |
Year | Amount | Yield |
---|---|---|
2007 | $9.36 | 14.30% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0.456 | 3.50% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.378 | 1.500 | 2.44 | 3.66 | [0 - 0.5] |
returnOnAssetsTTM | 0.0596 | 1.200 | 8.01 | 9.62 | [0 - 0.3] |
returnOnEquityTTM | 0.0742 | 1.500 | -0.287 | -0.431 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 14.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 12.49 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.368 | 1.500 | 3.51 | 5.27 | [0.2 - 2] |
debtRatioTTM | 0.00740 | -1.500 | 9.88 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 2.60 | 1.000 | -0.148 | -0.148 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.84 | 2.00 | 9.05 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.245 | 2.00 | -0.122 | -0.245 | [0 - 20] |
debtEquityRatioTTM | 0.00880 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.920 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0666 | 1.000 | -0.669 | -0.669 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.158 | 0.800 | -2.28 | -1.826 | [0.5 - 2] |
Total Score | 8.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.83 | 1.000 | 7.59 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0742 | 2.50 | -0.185 | -0.431 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.245 | 2.00 | -0.0815 | -0.245 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.84 | 2.00 | 9.05 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0118 | 1.500 | -3.25 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.378 | 1.000 | 3.06 | 0 | [0.1 - 0.5] |
Total Score | 1.515 |
Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。